日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay

利用仅血浆循环肿瘤DNA检测方法检测乳腺癌微小残留病灶并预测复发

Janni, W; Rack, B; Friedl, T W P; Hartkopf, A D; Wiesmüller, L; Pfister, K; Mergel, F; Fink, A; Braun, T; Mehmeti, F; Uhl, N; De Gregorio, A; Huober, J; Fehm, T; Müller, V; Rich, T A; Dustin, D J; Zhang, S; Huesmann, S T

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

DETECT 研究计划中接受筛查的转移性乳腺癌患者循环肿瘤细胞 HER2 状态的预后意义

Müller, V; Banys-Paluchowski, M; Friedl, T W P; Fasching, P A; Schneeweiss, A; Hartkopf, A; Wallwiener, D; Rack, B; Meier-Stiegen, F; Huober, J; Rübner, M; Hoffmann, O; Müller, L; Janni, W; Wimberger, P; Jäger, B; Pantel, K; Riethdorf, S; Harbeck, N; Fehm, T

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial

一项评估 FEC-Doc 和 FEC-Doc 联合吉西他滨作为高危早期乳腺癌辅助治疗的 III 期研究的毒性评估:SUCCESS-A 试验

Schröder, L; Rack, B; Sommer, H; Koch, J G; Weissenbacher, T; Janni, W; Schneeweiss, A; Rezai, M; Lorenz, R; Jäger, B; Schramm, A; Häberle, L; Fasching, P A; Friedl, T W P; Beckmann, M W; Scholz, C

Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.

评价两种不同的分析方法在原发性乳腺癌患者外周血中循环肿瘤细胞检测中的应用

Jaeger B A S, Jueckstock J, Andergassen U, Salmen J, Schochter F, Fink V, Alunni-Fabbroni M, Rezai M, Beck Th, Beckmann M W, Friese K, Friedl T W P, Janni W, Rack B

Does Non-Placement of a Drain in Breast Surgery Increase the Rate of Complications and Revisions?

乳腺手术中不放置引流管是否会增加并发症和再次手术的发生率?

Ebner, F K; Friedl, T W P; Degregorio, N; Reich, A; Janni, W; Rempen, A